Federal Legislation
Senate Proposes Ban on Chemical Abortion Drug
March 11, 2026
Senator Josh Hawley introduced the Safeguarding Women from Chemical Abortion Act aimed at banning the chemical abortion drug mifepristone by withdrawing FDA approval and criminalizing its distribution for abortion use. The bill also enables women harmed by the drug to sue manufacturers, which could significantly impact pharmaceutical procurement, regulatory oversight, and supply chain management for government agencies and contractors involved in drug manufacturing and distribution.
- Procurement professionals should anticipate potential changes in FDA drug approval status affecting contracts with manufacturers like Danco Laboratories.
- Pharmaceutical suppliers and contractors may face increased legal and regulatory risks related to mifepristone distribution.
- Agencies involved in healthcare procurement should evaluate the implications for sourcing and compliance with evolving legal frameworks.
- This legislative proposal signals heightened scrutiny on chemical abortion drugs, influencing future procurement strategies and risk assessments in the pharmaceutical sector.
As a pharmacist, I believe every drug approved in the United States must meet the highest standards of safety, transparency, and medical oversight.
— Congresswoman Diana Harshbarger
The science is clear: the chemical abortion drug is inherently dangerous to women and prone to abuse. Yet major companies like Danco Laboratories are making billions off it.
— Senator Josh Hawley
Agencies
Food and Drug Administration, United States Senate, United States House of Representatives
Vendors
Danco Laboratories